SONOMA PHARMACEUTICALS, INC. (NASDAQ:SNOA) Files An 8-K Amendment to Registrant’s Code of Ethics, or Waiver of a Provision of the Code of Ethics

SONOMA PHARMACEUTICALS, INC. (NASDAQ:SNOA) Files An 8-K Amendment to Registrant’s Code of Ethics, or Waiver of a Provision of the Code of Ethics

Story continues below

Item 5.05Amendments to the Registrants Code of Ethics, or Waiver
of a Provision of the Code of Ethics.

On January 17, 2017, our board of directors adopted changes to
our code of conduct. The code of conduct governs the conduct of
all our employees, directors and officers, including our
management. The changes to the code of conduct were made to
update the code to current best practices. In addition to some
clerical changes, the code of conduct now explicitly requires
employees, directors and officers to act honestly and ethically
in dealing with customers, business partners and others.
Furthermore, the code of conduct now explicitly extends the
confidentiality and conflicts of interest requirements to
directors and prohibits company loans. The code of conduct also
updated the disclosure, reporting and enforcement provisions. No
waivers have been granted under the code of conduct to date.

Item 9.01 Financial Statements and Exhibits.
14.1 Code of Conduct of Sonoma Pharmaceuticals, Inc., as revised
and adopted on January 17, 2017.


About SONOMA PHARMACEUTICALS, INC. (NASDAQ:SNOA)

Sonoma Pharmaceuticals, Inc., formerly Oculus Innovative Sciences, Inc., is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid. Microcyn is a small-molecule oxychlorine compound with antimicrobial and anti-inflammatory properties that, in clinical settings, reduces itch and pain associated with dermal irritations and wounds, such as sores, injuries and ulcers of dermal tissue. Lipogrid Technology contains selected lipids and a lipid precursor designed to penetrate the bilayers of the skin by blending with the natural lipid building blocks. Its products serve over five million patients across the globe by reducing infections, itch, pain, scarring and inflammatory responses. Its products are sold throughout the United States and internationally.

SONOMA PHARMACEUTICALS, INC. (NASDAQ:SNOA) Recent Trading Information

SONOMA PHARMACEUTICALS, INC. (NASDAQ:SNOA) closed its last trading session up +0.09 at 5.28 with 49,054 shares trading hands.

An ad to help with our costs